CONBA(SH:600572) Shang Hai Zheng Quan Bao·2025-04-11 20:45Core Viewpoint - The chairman of Zhejiang Kang En Bei Pharmaceutical Co., Ltd. proposed a cash dividend of 1.50 yuan per 10 shares for the fiscal year 2024, aiming to enhance shareholder returns and share the company's operational achievements [2][3]. Group 1: Proposal Details - The proposal is based on the company's confidence in the Chinese traditional medicine and health industry, and it aims to maintain the interests of all shareholders while ensuring the company's long-term development [2]. - The distribution will be calculated based on the total share capital after deducting shares held in the repurchase account, with the total amount adjusted if the share capital changes before the dividend distribution date [2][4]. Group 2: Board's Response - The board of directors has previously approved a share repurchase plan using 200 million to 400 million yuan, completing the repurchase of approximately 63.58 million shares at a total cost of about 299.92 million yuan [3]. - The board considers the chairman's proposal reasonable and feasible, planning to draft a profit distribution proposal after the 2024 annual financial report audit [3]. Group 3: Future Considerations - The company anticipates an increase in total share capital due to the stock option incentive plan, which may affect the dividend distribution proposal [4].